Pfizer, the US drug giant battling to win support for its £63bn approach for AstraZeneca, has unveiled a research partnership with five major UK universities. The American pharma company has announced a research tie-up with the Global Medical Excellence Cluster, which is made up of Cambridge University, Imperial College London, King’s College London, Queen Mary University London and Oxford University. It said the aim of the partnership is to develop new drugs for rare diseases, a range of around 6,000 disorders which each affect fewer than one in 2,000 people.
Help employers find you! Check out all the jobs and post your resume.
